Corium International,Inc. (NASDAQ:CORI) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
Submission of Matters to a Vote of Security Holders.
Corium International,Inc. (NASDAQ:CORI) Files An 8-K Submission of Matters to a Vote of Security Holders
On March 20, 2018, Corium International, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”).The stockholders of the Company voted in person or by proxy at the Annual Meeting on the following proposals, each of which is described in more detail in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on January 24, 2018:
1.To elect three Class Idirectorsto serve as members of our board of directors until the third annual meeting of stockholders following the Annual Meeting and until hissuccessor has been elected and qualified or until his earlier resignation or removal.
2.To ratify the appointment of Deloitte & ToucheLLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2018.
The voting results for each of these proposals are detailed below.
Each of the three nominees for director was elected to serve until the third annual meeting of stockholders following the Annual Meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal. The voting results were as follows:
|
Nominee |
For |
Withheld |
Broker Non-Votes |
|
Bhaskar Chaudhuri, Ph.D. |
20,398,932 |
1,059,365 |
2,163,841 |
|
Ronald Eastman |
20,164,894 |
1,293,403 |
2,163,841 |
|
Paul Goddard, Ph.D. |
20,420,127 |
1,038,170 |
2,163,841 |
|
2. |
Ratification of Appointment of Independent Registered Public Accounting Firm |
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2018.The voting results were as follows:
|
23 |
||
|
For |
Against |
Abstentions |
|
23,622,023 |
115 |
— |
About Corium International,Inc. (NASDAQ:CORI)
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.
